Catalyst Trade Alert *UPDATED With Chart* – Re-Bought Progenics (PGNX) – Price Target Opinion = $6.50

Disclosure: I bought 25k shares of $PGNX @ $5.45 Biorunup's Mark sold to go on vacation. Sheff remains bullish. we do as well. This is a pure catalyst trade which I talk about in my latest video. If Adcom for Relistor is good, I would expect a price back over $8.50.

Progenics has two upcoming catalysts:

  1. Progenics is expecting to announce data from its Phase II PSMA ADC trial at the American Society of Clinical Oncology meeting in January 2014.
  2. Progenics has a scheduled a tentative advisory panel meeting (ADCOM) in March (10th - 11th) to review an sNDA for Relistor expanded usage in OIC (opioid induced constipation) chronic pain.

In a December 6 press release it stated, "PSMA ADC is the most advanced antibody drug conjugate in clinical development to treat prostate cancer," said Robert J. Israel, M.D., Executive Vice President, Medical Affairs. "Based on the data seen with PSMA ADC in chemotherapy experienced patients, we have decided to explore whether this compound can also benefit men in the less clinically advanced chemotherapy naïve setting."

Trade thesis - Similar situation to $MACK before it ran from $2 to about $5. Chart indicates warrant holders/shorts are about to run the stock. I see little downside from here and an upside to at least $6.50, if not higher. Positive retail sentiment in the name, Baker Brothers LLC owning millions of shares, and other technical and fundamental factors make $PGNX a very attractive long shorter term trade.

PGNX

I have marked in white where I see bullish indicators. After hitting a high of $5.90. PGNX has consolidated and based from $5.20. I predicted a move to as low as $5.17, and it made that move, but a bit lower to $5.11. Take note of the inverted H&S in money flow and accumulation/distribution. Additionally, we see a nice rounding pattern setting  the next leg up, which should be $6.50 or so in my opinion.

I look for the move to occur in the next 5 trading sessions.

Minimum price target opinion is $6.50, with a possible move over $7, depending on market conditions.

For additional information on Progenics, see this interesting Seeking Alpha article here.

Scott

, , , , , , , , , , , , , , , , , , , ,

Post navigation

Leave a Reply